相似文献
1
Ipilimumab: from preclinical development to future clinical perspectives in melanoma.
Future Oncol. 2017 Mar;13(7):625-636. doi: 10.2217/fon-2016-0385. Epub 2016 Nov 24.
2
Immune Checkpoint Therapy in Melanoma.
Cancer J. 2016 Mar-Apr;22(2):73-80. doi: 10.1097/PPO.0000000000000183.
3
CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
Cancer Med. 2015 May;4(5):661-72. doi: 10.1002/cam4.371. Epub 2015 Jan 25.
4
Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.
Clin Cancer Res. 2011 Nov 15;17(22):6958-62. doi: 10.1158/1078-0432.CCR-11-1595. Epub 2011 Sep 7.
5
Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies.
Tumori. 2013 Nov-Dec;99(6):302e-5e. doi: 10.1700/1390.15474.
6
Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials.
Cancer Med. 2016 Jul;5(7):1481-91. doi: 10.1002/cam4.732. Epub 2016 May 11.
7
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
8
Cytotoxic T-lymphocyte antigen-4 blockade in melanoma.
Clin Ther. 2015 Apr 1;37(4):755-63. doi: 10.1016/j.clinthera.2015.02.003. Epub 2015 Mar 6.
9
CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Clin Cancer Res. 2013 Oct 1;19(19):5300-9. doi: 10.1158/1078-0432.CCR-13-0143.
10
Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Pharmacol Res. 2012 Jan;65(1):9-22. doi: 10.1016/j.phrs.2011.09.002. Epub 2011 Sep 10.
引用本文的文献
1
Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications.
Immun Inflamm Dis. 2025 Apr;13(4):e70196. doi: 10.1002/iid3.70196.
2
Targeting Matrix Metalloproteinases and Their Inhibitors in Melanoma.
Int J Mol Sci. 2024 Dec 18;25(24):13558. doi: 10.3390/ijms252413558.
3
Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy.
Pharmaceuticals (Basel). 2024 Aug 5;17(8):1031. doi: 10.3390/ph17081031.
4
Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics.
Clin Exp Med. 2023 Dec;23(8):4297-4322. doi: 10.1007/s10238-023-01201-2. Epub 2023 Oct 7.
5
Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic.
Glob Chall. 2022 Oct 20;7(1):2200094. doi: 10.1002/gch2.202200094. eCollection 2023 Jan.
6
Injectable Hydrogel as a Unique Platform for Antitumor Therapy Targeting Immunosuppressive Tumor Microenvironment.
Front Immunol. 2022 Jan 17;12:832942. doi: 10.3389/fimmu.2021.832942. eCollection 2021.
7
Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma.
Biomedicines. 2020 Sep 3;8(9):327. doi: 10.3390/biomedicines8090327.
8
Development of oncolytic virotherapy: from genetic modification to combination therapy.
Front Med. 2020 Apr;14(2):160-184. doi: 10.1007/s11684-020-0750-4. Epub 2020 Mar 7.
9
Humanized mice for immune checkpoint blockade in human solid tumors.
Am J Clin Exp Urol. 2019 Oct 15;7(5):313-320. eCollection 2019.
10
Small-Molecule Targets in Tumor Immunotherapy.
Nat Prod Bioprospect. 2018 Aug;8(4):297-301. doi: 10.1007/s13659-018-0177-7. Epub 2018 Jul 5.
本文引用的文献
1
Cancer statistics, 2016.
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
2
Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.
Cancer Chemother Pharmacol. 2015 Nov;76(5):969-75. doi: 10.1007/s00280-015-2870-0. Epub 2015 Sep 25.
3
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
N Engl J Med. 2015 Sep 24;373(13):1270-1. doi: 10.1056/NEJMc1509660.
4
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
J Clin Oncol. 2015 Oct 1;33(28):3193-8. doi: 10.1200/JCO.2015.60.8448. Epub 2015 Aug 17.
5
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.
6
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26.
7
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
N Engl J Med. 2015 May 21;372(21):2006-17. doi: 10.1056/NEJMoa1414428. Epub 2015 Apr 20.
8
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
Lancet Oncol. 2015 May;16(5):522-30. doi: 10.1016/S1470-2045(15)70122-1. Epub 2015 Mar 31.
9
Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature.
J Oncol Pharm Pract. 2016 Jun;22(3):537-42. doi: 10.1177/1078155215572932. Epub 2015 Feb 23.
10
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
J Clin Oncol. 2015 Jun 10;33(17):1889-94. doi: 10.1200/JCO.2014.56.2736. Epub 2015 Feb 9.
Zotero 插件